Versant Vantage
Startup rounds since 2014 with a Versant Vantage investor on the board, and the firm's own fund filings.
Raises
56
since 2014
Unannounced
0
no announcement found, of those filed since 2025
Funds
3
fund filings under the firm's name
Rounds
- Lycia Therapeutics, Inc.$75M
- Nexo Therapeutics, Inc.$60M
- Pep2Tango Therapeutics, Inc.$16.7M
- 858 Therapeutics, Inc.$25.2M
- Santa Ana Bio, Inc.$20M
- Lycia Therapeutics, Inc.$107M
- Firefly Bio, Inc.$40M
- Jnana Therapeutics Inc.$107M
- Lenz Therapeutics, Inc.$83.5M
- Santa Ana Bio, Inc.$35.3M
- Lenz Therapeutics, Inc.$49M
- March Therapeutics, Inc.$20.3M
- RayzeBio, Inc.$168M
- Ventus Therapeutics U.S., Inc.$70M
- Lycia Therapeutics, Inc.$70.1M
- Jnana Therapeutics Inc.$50M
- Turnstone Biologics Corp.$80M
- RayzeBio, Inc.$109M
- Santa Ana Bio, Inc.$8.02M
- 858 Therapeutics, Inc.$20M
- Ventus Therapeutics U.S., Inc.$100M
- Monte Rosa Therapeutics, Inc.$95M
- Graphite Bio, Inc.$151M
- Century Therapeutics, Inc.Undisclosed
- Vividion Therapeutics, Inc.$135M
- RayzeBio, Inc.$105M
- RayzeBio, Inc.$15M
- Chinook Therapeutics U.S., Inc.$115M
- Monte Rosa Therapeutics, Inc.$48M
- Jengu Therapeutics, Inc.$5M
- Ventus Therapeutics U.S., Inc.$16.8M
- Lycia Therapeutics, Inc.$25.4M
- 858 Therapeutics, Inc.$20.1M
- Tempest Therapeutics, Inc.$83.2M
- Black Diamond Therapeutics, Inc.$85M
- Chinook Therapeutics U.S., Inc.$65M
- Black Diamond Therapeutics, Inc.$44.2M
- Vividion Therapeutics, Inc.$82M
- Oyster Point Pharma, Inc.$85M
- Turnstone Biologics Corp.$42.1M
- VenatoRx Pharmaceuticals, Inc.$27.1M
- Black Diamond Therapeutics, Inc.$5M
- Mistral Therapeutics, Inc.$25.9M
- Pandion Therapeutics, Inc.$21.6M
- Bird Rock Bio, Inc.$2.5M
- Travus Therapeutics, Inc.$750K
- Bird Rock Bio, Inc.$5M
- Inception IBD, Inc.$6.92M
- Audentes Therapeutics, Inc.$65M
- Laguna Pharmaceuticals, Inc.$4.48M
- Kanyos Bio, Inc.$6.01M
- Kanyos Bio, Inc.$10.4M
- ChanRx Corp.$16.6M
- Audentes Therapeutics, Inc.$42.5M
- Inception 5, Inc.$5M
- Ruiyi, Inc.$5M
By year
| Year | Raises | Unannounced |
|---|---|---|
| 2026 | 2 | 0 |
| 2024 | 6 | — |
| 2023 | 2 | — |
| 2022 | 4 | — |
| 2021 | 11 | — |
| 2020 | 9 | — |
| 2019 | 6 | — |
| 2018 | 4 | — |
| 2017 | 1 | — |
| 2016 | 2 | — |
| 2015 | 6 | — |
| 2014 | 3 | — |
Raises are checked for an announcement from 2025 on.
Funds
The firm's own fund filings, each at its latest filing.
| Fund | Filed | Size | Raised |
|---|---|---|---|
| Versant Vantage III, L.P. | 7 Apr 2023 | $299M | $299M |
| Versant Vantage II, L.P. | 15 Apr 2021 | $254M | $254M |
| Versant Vantage I, L.P. | 8 Mar 2019 | $150M | — |
Listed because a Versant Vantage fund's filing names a director of each company. A name match is not a verified identity.